Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study is a double-masked, randomized, placebo-controlled study of the safety and
preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance
injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be
effective in the treatment of neovascular AMD.